() experienced a significant drop in short interest for the month of march. On March 31, there were 300 shares of short interest, which is a significant drop from 1,500 shares on March 15. The short-interest rate is 0.1 days based on an average trading of 3,200 shares.
Biostage Stock Performance
The stock rose $0.25 to $6.40 during Friday's midday trading. The average trading volume for the stock is 2,181. The market cap is $78.14 Million, the PE ratio is -6.60, and beta is -0.95. The company has a simple moving-average of $6.03 for the last fifty days and $6.29 for the past two hundred days. Get Rating
Biostage, Inc. is a biotechnology firm that develops organ implants for the treatment of congenital defects, tumors, and life-threatening diseases of the esophagus, the bronchus, and the trachea. Cellframe technology is used to activate the body's natural healing process and stimulate signaling pathways.
MarketBeat.com offers a FREE daily email newsletter